- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
USPSTF Stands by 2-Year Mammography Decision
Women with an average risk of breast cancer should have screening mammography every 2 years during ages 50 to 74, according to updated recommendations from the United States Preventive Services Task Force.
Women with an average risk of breast cancer should have screening mammography every 2 years during ages 50 to 74, according to updated recommendations from the United States Preventive Services Task Force (USPSTF).
After reviewing available data, the panel concluded that women, ages 60 to 69, derive the greatest benefit from screening mammography in terms of preventing breast cancer death.
Selected women 40 to 49 might reduce their risk of dying of breast cancer with regular mammographic screening, but the benefit is much smaller as compared with older women and leads to too many false-positive tests and unnecessary breast biopsies, the USPSTF concluded in a draft document posted on the task force website. The posting begins a 30-day public comment period.
With the release of the draft, the USPSTF stands by most of its previous recommendation, published in 2009.
Read more at Medpage Today: http://bit.ly/1QeJCFO
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
